ALL-trans retinoic acid (ATRA) may improve results of chemotherapy in poor prognosis non-APL AML and MDS: A randomized study.

被引：0
|
作者：
Estey, E [1 ]
Beran, M [1 ]
Pierce, S [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,HOUSTON,TX 77030
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1851 / 1851
页数：1
相关论文
共 50 条
  • [31] Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL)
    Ravandi, Farhad
    Estey, Elihu H.
    Cortes, Jorge E.
    O'Brien, Susan
    Pierce, Sherry A.
    Brandt, Mark
    Ferrajoli, Alessandra
    Borthakur, Gautam
    Konopleva, Marina
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Kantarjian, Hagop
    BLOOD, 2010, 116 (21) : 472 - 472
  • [32] Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study
    Frerichs, Kristine A.
    Minnema, Monique C.
    Levin, Mark-David
    Broyl, Annemiek
    Bos, Gerard
    Kersten, Marie Jose
    Mutis, Tuna
    Verkleij, Christie P. M.
    Bosman, Patricia W. C.
    Klein, Saskia K.
    Zweegman, Sonja
    Sonneveld, Pieter
    Van de Donk, Niels W. C. J.
    BLOOD, 2019, 134
  • [33] Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients
    Lubbert, Michael
    Grishina, Olga
    Schmoor, Claudia
    Schlenk, Richard F.
    Jost, Edgar
    Krauter, Jurgen
    Heuser, Michael
    Thol, Felicitas
    Schittenhelm, Marcus M.
    Salih, Helmut R.
    Kundgen, Andrea
    Germing, Ulrich
    Gotze, Katharina
    Lindemann, Hans-Walter
    Muller-Tidow, Carsten
    Heil, Gerhard
    Bug, Gesine
    Schwanen, Carsten
    Giagounidis, Aristoteles
    Scholl, Sebastian
    Neubauer, Andreas
    Brugger, Wolfram
    de Wit, Maike
    Schroll, Sebastian
    Kremers, Stephan
    Lange, Elisabeth
    Kullmer, Johannes
    Behringer, Dirk
    Egger, Matthias
    Dresel, Irmgard
    Dechow, Tobias
    Niederwieser, Dietger
    Wass, Maxi
    May, Annette M.
    Wasch, Ralph
    Dohner, Konstanze
    Ganser, Arnold
    Hackanson, Bjorn
    Dohner, Hartmut
    BLOOD, 2016, 128 (22)
  • [34] All-trans retinoic acid (ATRA) upregulation of Bfl-1/A1 prevents apoptosis during differentiation induction and diminishes chemotherapy cytotoxicity of acute promyelocytic leukemia (APL) cells.
    Jing, YK
    Xia, LJ
    Waxman, S
    BLOOD, 2000, 96 (11) : 309A - 309A
  • [35] Phase VII study of the combination of 5-azacytidine(5-AC), all-trans retinoic acid (ATRA) and valproic Acid (VPA) in patients with myelodysplastic syndrome (MDS) and leukemia.
    Soriano, A. O.
    Yang, H.
    Verstovsek, S.
    Wierda, W.
    Koller, C.
    Estrov, Z.
    Ouzounian, S.
    Kantarjian, H.
    Issa, J.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 352S - 352S
  • [36] Cellworks Omics Biology Model (CBM) to predict therapy response and identify biomarkers for all-trans retinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML).
    Howard, Scott C.
    Kumar, Ansu
    Grover, Himanshu
    Patil, Vivek
    Agrawal, Ashish
    Tyagi, Anuj
    Mohapatra, Subrat
    Azam, Humera
    Raju, Karthik Sundara
    Sauban, Mohammed
    Raman, Rahul K.
    Lunkad, Neelesh
    Mitra, Upasana
    Poornachandra, G.
    Mundkur, Nirjhar
    Gupta, Neha
    Chauhan, Jyoti
    Khandelwal, Swati
    Kapoor, Shweta
    Castro, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Chemotherapy and all-trans retinoic acid in patients >60 years with acute myeloid leukemia:: The randomized multicenter treatment trial AML HD98-B.
    Fröhling, S
    Schlenk, RF
    Biedermann, HG
    del Valle, F
    Dreger, P
    Fischer, JT
    Glasmacher, A
    Götze, K
    Grimminger, W
    Haas, R
    Hahn, U
    Hartmann, F
    Hufnagal, D
    Koller, E
    Mergenthaler, HG
    Waterhouse, C
    Weber, C
    Weber, W
    Döhner, K
    Döhner, H
    BLOOD, 2000, 96 (11) : 722A - 722A
  • [38] Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.
    Nazha, Aziz
    Bueso-Ramos, Carlos E.
    Faderl, Stefan
    Estey, Elihu H.
    O'Brien, Susan M.
    Farnandez, Michael
    Nguyen, Martin
    Koller, Charles
    Freireich, Emil
    Beran, Miloslav
    Pierce, Sherry
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    BLOOD, 2012, 120 (21)
  • [39] Protein kinase C (PKC)-based anti-leukemic therapy: A randomized phase II trial of all-trans retinoic acid (ATRA) and bryostatin 1 (BRYO) in patients (PTS) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Stone, RM
    Galinsky, I
    Berg, D
    Daftary, F
    Kinchla, N
    Zaleskas, JM
    Xu, G
    Liou, JR
    BLOOD, 1998, 92 (10) : 631A - 631A
  • [40] Clinical study of combining arsenic trioxide (As2O3), all-trans retinoic acid (ATRA) and idarubicin (IDA) for induction therapy on the patients with relapsed acute promyelocytic leukemia(APL)
    Ma, J.
    Liu, J.
    Zhang, B.
    Zhan, Z.
    Jin, M.
    Wang, L.
    Gong, T.
    Shao, X.
    EJC SUPPLEMENTS, 2005, 3 (02): : 284 - 284
12345